SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
复制标题
DOI：
10.1016/j.cell.2021.03.036
复制
发表时间：
2021-04-29
期刊：
影响因子：
64.5
通讯作者：
Pöhlmann S
中科院分区：
文献类型：
--
作者：
Hoffmann M;Arora P;Groß R;Seidel A;Hörnich BF;Hahn AS;Krüger N;Graichen L;Hofmann-Winkler H;Kempf A;Winkler MS;Schulz S;Jäck HM;Jahrsdörfer B;Schrezenmeier H;Müller M;Kleger A;Münch J;Pöhlmann S
SARS-CoV-2/COVID-19的全球传播正在破坏全球卫生系统和经济。重组或疫苗诱导的中和抗体用于对抗COVID-19大流行。然而，最近出现的SARS-CoV-2变体B.1.1.7（英国），B.1.351（南非）和P.1（巴西）在病毒刺突（S）蛋白中含有突变，可能会改变病毒-宿主细胞相互作用并赋予对抑制剂和抗体的抗性。在这里，我们使用假颗粒表明，所有变体进入人类细胞都容易受到进入抑制剂可溶性ACE 2、Camostat、EK-1和EK-1-C4的阻断。相比之下，B.1.351和P.1变体的进入对用于COVID-19治疗的抗体具有部分（Casirivimab）或完全（Bamlanivimab）抗性。此外，来自恢复期COVID-19患者的血浆和来自BNT 162 b2疫苗接种个体的血清对这些变体的进入抑制效率较低。这些结果表明，SARS-CoV-2可能逃避中和抗体反应，这对遏制大流行的努力具有重要意义。对SARS-CoV-2变异体B.1.1.7、B.1.351和P.1的比较表明，尽管B.1.351和P.1变异体逃避了感染和接种疫苗时诱导的抗体应答，并逃避了某些治疗性抗体，但临床评价中的抑制剂仍然有效地阻断了进入。
The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the COVID-19 pandemic. However, the recently emerged SARS-CoV-2 variants B.1.1.7 (UK), B.1.351 (South Africa), and P.1 (Brazil) harbor mutations in the viral spike (S) protein that may alter virus-host cell interactions and confer resistance to inhibitors and antibodies. Here, using pseudoparticles, we show that entry of all variants into human cells is susceptible to blockade by the entry inhibitors soluble ACE2, Camostat, EK-1, and EK-1-C4. In contrast, entry of the B.1.351 and P.1 variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment. Moreover, entry of these variants was less efficiently inhibited by plasma from convalescent COVID-19 patients and sera from BNT162b2-vaccinated individuals. These results suggest that SARS-CoV-2 may escape neutralizing antibody responses, which has important implications for efforts to contain the pandemic. Comparison of the SARS-CoV-2 variants B.1.1.7, B.1.351, and P.1 shows that inhibitors under clinical evaluation are still effective in blocking entry, though the B.1.351 and P.1 variants evade antibody responses induced upon infection as well as vaccination and evade certain therapeutic antibodies.
登录
查看更多内容
影响因子：
5.4
作者：
Heurich, Adeline;Hofmann-Winkler, Heike;Poehlmann, Stefan
通讯作者：
Poehlmann, Stefan
DOI：
10.1056/nejmoa2029849
发表时间：
2021-01-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Chen P;Nirula A;Heller B;Gottlieb RL;Boscia J;Morris J;Huhn G;Cardona J;Mocherla B;Stosor V;Shawa I;Adams AC;Van Naarden J;Custer KL;Shen L;Durante M;Oakley G;Schade AE;Sabo J;Patel DR;Klekotka P;Skovronsky DM;BLAZE-1 Investigators
通讯作者：
BLAZE-1 Investigators
影响因子：
5.4
作者：
Kleine-Weber H;Elzayat MT;Wang L;Graham BS;Müller MA;Drosten C;Pöhlmann S;Hoffmann M
通讯作者：
Hoffmann M
影响因子：
56.9
作者：
Cai, Yongfei;Zhang, Jun;Chen, Bing
通讯作者：
Chen, Bing
REGN-COV2抗体预防和治疗恒河猕猴和仓鼠中的SARS-COV-2感染。
DOI：
10.1126/science.abe2402
发表时间：
2020-11-27
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Baum A;Ajithdoss D;Copin R;Zhou A;Lanza K;Negron N;Ni M;Wei Y;Mohammadi K;Musser B;Atwal GS;Oyejide A;Goez-Gazi Y;Dutton J;Clemmons E;Staples HM;Bartley C;Klaffke B;Alfson K;Gazi M;Gonzalez O;Dick E Jr;Carrion R Jr;Pessaint L;Porto M;Cook A;Brown R;Ali V;Greenhouse J;Taylor T;Andersen H;Lewis MG;Stahl N;Murphy AJ;Yancopoulos GD;Kyratsous CA
通讯作者：
Kyratsous CA